3 August 2010
Advanced Medical Solutions Group plc
(“AMS” or “the Company”)
AMS Strengthens Senior Management Team
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, announces that it has strengthened its senior management team with key appointments.
Clare Holden has been appointed Vice President of Research and Development. Clare has over 20 years of process and new product development experience with global organisations such as Smith & Nephew where her last position was as Vice President of New Product Development for their Hull based Wound Management Division. Most recently, Clare was Head of Project Transformations at Siemens’ Automation & Drives Division in Manchester.
In addition, Steve Platt joins as General Manager of AMS’s new world class Winsford facility. Steve brings 16 years of experience in industrial manufacturing and production with multinational organisations including Toyota Manufacturing (UK), JCB Transmissions, RWD Technologies and, most recently, Nilfisk Advance. He has a proven track record formaximising business performance through the implementation of lean project management techniques, including green field site responsibilities.
Chris Meredith, COO of Advanced Medical Solutions commented:
“We are delighted to announce these latest additions to our senior management team, strengthening our research and development and general operational functions. The appointments follow on from the appointments earlier in the year of Brian Dowd, who joined us from Covidien to head up our US Commercial team, and Dr. Andrew Garland, who joined us from 3M to head our European Commercial Team.
“The additions add experience and enthusiasm to our existing team, as we develop our infrastructure to take the Company through the next exciting period of growth and realise the opportunities open for our innovative product portfolio.“
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc
Don Evans, Chief Executive Officer Tel: +44 (0) 1606 545508
Chris Meredith, Chief Operating Officer
Mary Tavener, Finance Director
John West / Andrew Dunn / Chris Munden Tel: +44 (0) 20 7920 3150
Notes to Editors:
AMS advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foam. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. The inclusion of silver adds a proven effectiveness against antibiotic resistant bacteria.
AMS wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.
AMS employs 240 people in three locations (Winsford, Plymouth and the Netherlands). In 2009, AMS delivered a 19% increase in revenues and a 51% increase in operating profit before exceptionals. The business has an experienced management team, whose stated aim is to grow the business both organically and by exploring selective acquisition opportunities. The Board has announced its intention to recommend a maiden dividend for the year ended 31st December 2010.
This information is provided by RNS